Healthcare

Medicus Pharma outlines CD228V strategy as SkinJect SPAC proposal remains non-binding

Medicus Pharma said it will direct incremental investment towards CD228V while pursuing a separate listing for SkinJect and maintaining Teverelix readiness for potential partnerships.

Published:
Reading Time
4 min

Medicus Pharma Ltd. (NASDAQ:MDCX) is set to outline its development priorities for CD228V, SkinJect® and Teverelix® alongside its third-quarter 2026 financial update. The company said it plans to focus incremental development spending on CD228V, pursue a separate public listing and dedicated financing for SkinJect, and keep Teverelix ready for potential partnering.

#Conference call to cover Pfizer agreement and portfolio plans

The company scheduled its business update conference call for Monday, November 9, 2026, at 11:30 a.m. ET, following the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Participants were expected to include Raza Bokhari, Executive Chairman and Chief Executive Officer; Carolyn Bonner, President and Chief Financial Officer; and Faisal Mehmud, Chief Medical Officer.

Management was expected to discuss the scientific and clinical basis for Medicus’ CD228V co-development and license agreement with Pfizer Inc., the proposed SkinJect transaction with an undisclosed special purpose acquisition company, and the company’s approach to capital allocation.

#CD228V development to focus initially on melanoma

Medicus said its decision on CD228V was informed by its review of clinical data from Seagen’s open-label Phase 1 study of the predecessor molecule SGN-CD228A. The study enrolled 88 patients with advanced solid tumours, including melanoma and non-small cell lung cancer. Detailed results from the study have not yet been publicly disclosed.

CD228V, also known as PF-08046031, is a second-generation antibody-drug conjugate directed against CD228, or melanotransferrin. The company said Pfizer modified the linker and payload characteristics of the molecule while using its vedotin linker-payload platform. Medicus said these changes were intended to balance drug exposure, tolerability and anti-tumour activity.

The company intends to begin with melanoma that has relapsed, become refractory or resisted immunotherapy. Medicus believes CD228V has the potential to achieve an objective response rate exceeding 30% in melanoma, based on its assessment of the predecessor data and the revised construct. That potential remains to be demonstrated in clinical trials of CD228V.

Any future monotherapy registration strategy would depend on durable responses, an acceptable safety profile and applicable regulatory requirements. The company also said evidence from development could support future licensing, co-development or other strategic opportunities, although the rights, economics and clinical maturity of comparable Pfizer collaborations differ.

#SkinJect transaction remains subject to further conditions

Medicus said the proposed SkinJect® transaction is intended to create a separately listed company with access to public capital markets and dedicated financing for Gorlin syndrome development. Under the proposed structure, Medicus seeks to retain majority economic and voting ownership of the combined company while concentrating incremental investment on precision oncology.

The non-binding letter of intent with the undisclosed SPAC contemplates an approximately $135 million pre-money enterprise valuation for SkinJect. The proposed terms would involve the SPAC acquiring 100% of SkinJect in exchange for newly issued common shares of the combined company.

Concurrent equity financing is contemplated at closing to support the SKNJCT-005 study in Gorlin syndrome and preparation and submission of a potential New Drug Application. Medicus currently projects approximately $3 million over the next two years for the programme, subject to execution and regulatory requirements.

Medicus currently anticipates completing the proposed transaction during the first half of 2027. However, the letter of intent is non-binding. The company said there can be no assurance that definitive agreements will be signed, financing will be secured, Medicus will retain majority ownership, or the transaction will close within that timeframe or at all. Further terms and conditions apply to the proposed transaction.

#Teverelix remains positioned for potential partnerships

Medicus said it is seeking partners with the capabilities and resources to advance Teverelix® in urology, advanced prostate cancer and women’s health. The company intends to maintain essential resources for the programme while pursuing those partnerships.

The optimised prostate cancer protocol remains subject to FDA feedback. Medicus said its approach is intended to preserve programme readiness while it assesses potential partnering opportunities.

#Funding and third-quarter financial update

During the nine-month period ended September 30, 2026, Medicus raised approximately $42.6 million through equity and secured debt financings, net of issuance costs. After approximately $6.4 million in debt repayments, net cash provided by financing activities was $36.2 million.

Nine-month operating expenses included $9.6 million of research and development expense and a $10.0 million acquired in-process research and development charge. On September 30, 2026, the company held $5.0 million in cash and cash equivalents and $8.1 million in restricted cash, for a combined total of $13.1 million.

Medicus also said management anticipates a substantial reduction in operating expenses in the coming quarters as spending is aligned with the company’s portfolio priorities.

#Key Takeaways

  • Medicus Pharma plans to direct incremental development investment towards CD228V, with an initial focus on relapsed, refractory or immunotherapy-resistant melanoma.
  • The company’s belief that CD228V could achieve an objective response rate exceeding 30% in melanoma remains subject to confirmation in clinical trials.
  • The proposed SkinJect SPAC transaction is based on a non-binding letter of intent and is not assured to proceed or close.
  • Medicus is seeking partners for Teverelix, while its optimised prostate cancer protocol remains subject to FDA feedback.
  • The company raised approximately $42.6 million through equity and secured debt financings during the nine months ended September 30, 2026.

Original source: Read original article

Frequently Asked Questions